Shrushma Loi

505 total citations
11 papers, 122 citations indexed

About

Shrushma Loi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Shrushma Loi has authored 11 papers receiving a total of 122 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in Shrushma Loi's work include HER2/EGFR in Cancer Research (6 papers), Advanced Breast Cancer Therapies (4 papers) and Breast Cancer Treatment Studies (4 papers). Shrushma Loi is often cited by papers focused on HER2/EGFR in Cancer Research (6 papers), Advanced Breast Cancer Therapies (4 papers) and Breast Cancer Treatment Studies (4 papers). Shrushma Loi collaborates with scholars based in United Kingdom, Australia and Switzerland. Shrushma Loi's co-authors include David Cameron, Rupert Bartsch, Giuseppe Curigliano, Guy Jérusalem, Rudolf Maibach, Janet Dunn, Mario Campone, Louise Hiller, Laura Biganzoli and Rina Hui and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Shrushma Loi

10 papers receiving 118 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shrushma Loi United Kingdom	6	117	40	39	36	26	11	122
Shakeela Bahadur United States	6	144 1.2×	21 0.5×	54 1.4×	38 1.1×	54 2.1×	8	174
Yuriy Vinnyk Ukraine	4	78 0.7×	12 0.3×	55 1.4×	22 0.6×	60 2.3×	7	113
Bronwyn D. Mixter United States	4	70 0.6×	30 0.8×	9 0.2×	34 0.9×	17 0.7×	5	100
Cristina Viaplana Spain	5	64 0.5×	16 0.4×	15 0.4×	34 0.9×	23 0.9×	19	82
Anne-Laure Vallier United Kingdom	5	76 0.6×	44 1.1×	47 1.2×	22 0.6×	5 0.2×	8	101
N. Girard France	4	81 0.7×	15 0.4×	11 0.3×	73 2.0×	19 0.7×	24	110
Karim Amrane France	5	105 0.9×	11 0.3×	20 0.5×	70 1.9×	26 1.0×	18	133
Jagdish Shetty United States	4	79 0.7×	12 0.3×	13 0.3×	40 1.1×	8 0.3×	7	89
Wenqin Feng United States	5	124 1.1×	23 0.6×	48 1.2×	75 2.1×	12 0.5×	9	149

Countries citing papers authored by Shrushma Loi

Since Specialization

Citations

This map shows the geographic impact of Shrushma Loi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shrushma Loi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shrushma Loi more than expected).

Fields of papers citing papers by Shrushma Loi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shrushma Loi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shrushma Loi. The network helps show where Shrushma Loi may publish in the future.

Co-authorship network of co-authors of Shrushma Loi

This figure shows the co-authorship network connecting the top 25 collaborators of Shrushma Loi. A scholar is included among the top collaborators of Shrushma Loi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shrushma Loi. Shrushma Loi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Graff, Stephanie L., et al.. (2024). 261TiP TROPION-Breast05: Phase (Ph) III study of datopotamab deruxtecan (Dato-DXd) ± durvalumab (D) vs chemotherapy (CT) + pembrolizumab (pembro) in patients (pts) with PD-L1+ locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC). ESMO Open. 9. 103282–103282. 4 indexed citations

Opdam, Mark, Katarzyna Jóźwiak, Michael Hauptmann, et al.. (2020). 159O Prognostic value of tumour infiltrating lymphocytes in young triple negative breast cancer patients who did not receive adjuvant systemic treatment; by the PARADIGM study group. Annals of Oncology. 31. S303–S303. 16 indexed citations

Hiller, Louise, Janet Dunn, Shrushma Loi, et al.. (2018). Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results. BMC Cancer. 18(1). 391–391. 5 indexed citations

Loi, Shrushma, Andrea Gombos, Rina Hui, et al.. (2018). Abstract GS2-06: Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: Results from the PANACEA (IBCSG 45-13/BIG 4-13/KEYNOTE-014) study. Cancer Research. 78(4_Supplement). GS2–6. 37 indexed citations

Earl, Helena, Louise Hiller, Anne-Laure Vallier, et al.. (2018). PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.. Journal of Clinical Oncology. 36(15_suppl). 506–506. 40 indexed citations

Loi, Shrushma, Anita Giobbie‐Hurder, Andrea Gombos, et al.. (2017). Phase Ib/II study evaluating safety and efficacy of Pembrolizumab and Trastuzumab in patients with Trastuzumab-resistant HER2-positive advanced breast cancer : results from the PANACEA study (IBCSG 45-13/BIG 4-13/KEYNOTE-014). Open Repository and Bibliography (University of Liège). 5 indexed citations

Dièras, Véronique, HS Rugo, Karen A. Gelmon, et al.. (2017). Abstract P4-22-07: Long-term safety of palbociclib in combination with endocrine therapy in treatment-naive and previously treated women with HR+ HER2– advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies. Cancer Research. 77(4_Supplement). P4–22. 1 indexed citations

Loi, Shrushma, Fabrice André, Rudolf Maibach, et al.. (2016). Abstract OT3-01-05: PANACEA (IBCSG 45-13/BIG 4-13): A phase Ib/II trial evaluating the efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant, HER2-positive, metastatic breast cancer. Cancer Research. 76(4_Supplement). OT3–1. 9 indexed citations

Harbeck, Nadia, Massimo Cristofanilli, Jungsil Ro, et al.. (2015). 1815 A double blind phase 3 trial of fulvestrant with placebo or palbociclib in pre- and post-menopausal women with hormone receptor-positive (HR+ve), HER2-negative (HER2-ve) metastatic breast cancer (MBC) that progressed on prior endocrine therapy (PALOMA 3): Detailed analysis of patient-reported outcomes. European Journal of Cancer. 51. S270–S271. 3 indexed citations

10.

Earl, Helena, David Cameron, David Miles, et al.. (2014). PERSEPHONE is a randomised phase III controlled trial comparing six months of trastuzumab to the standard 12 months in patients with HER2 positive early breast cancer. European Journal of Surgical Oncology. 40(5). 619–619. 1 indexed citations

11.

Poole, C. J., Louise Hiller, Helen Howard, et al.. (2006). Tolerability of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy in the randomized phase III tAnGo trial for invasive higher risk early stage breast cancer.. Breast Cancer Research and Treatment. 100. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact